logo
Evidence of one of Scotland's earliest human populations uncovered

Evidence of one of Scotland's earliest human populations uncovered

The stones have been dated to a period known as the Late Upper Palaeolithic (LUP) from around 11,500 to 11,000 years ago.
The wider context of them is yet to be analysed in detail, but were found in sites discovered by Karen Hardy, professor of Prehistoric Archaeology at the university and local archaeologist Martin Wildgoose.
Their discovery means the west coast now represents the largest concentration of evidence for these early human populations anywhere in Scotland and show how they ventured much further north than previously believed.
The discoveries have been announced in a paper entitled 'At the far end of everything: A likely Ahrensburgian presence in the far north of the Isle of Skye, Scotland'.
Professor Karen Hardy said: 'This is a hugely significant discovery which offers a new perspective on the earliest human occupation yet known, of north-west Scotland.'
The team included people from the universities of Leeds, Sheffield, Leeds Beckett and Flinders in Australia and they worked together to reconstruct the local landscape and changing sea levels.
The period is immediately after the Younger Dryas, also known as the Loch Lomond Stadial, when much of the west of Scotland was buried under ice.
Groups of nomadic hunter-gathers who were most likely of the Ahrensburgian culture and from Northern Europe, crossed an area now covered by the North Sea known as Doggerland and established themselves on Skye.
Professor Hardy added: 'The journey made by these pioneering people who left their lowland territories in mainland Europe to travel northwards into the unknown, is the ultimate adventure story.
'As they journeyed northwards, most likely following animal herds, they eventually reached Scotland, where the western landscape was dramatically changing as glaciers melted and the land rebounded as it recovered from the weight of the ice.
'A good example of the volatility they would have encountered can be found in Glen Roy, where the world-famous Parallel Roads provide physical testament to the huge landscape changes and cataclysmic floods that they would have encountered, as they travelled across Scotland.'
Read More
When they reached Skye, it is believed they crafted tools from stone found locally and deliberately and strategically chose where to base themselves to have good access to coastal and riverine resources as well as natural materials like Ochre which was highly valued.
The paper concludes by saying: 'While the number of Ahrensburgian findspots is low, they are spread widely across Scotland, including from the islands of Tiree, Orkney and Islay, that also imply significant sea journeys, suggesting a larger population than the number of finds might imply.
'To date, all Late Upper Palaeolithic (LUP) sites in Scotland have been discovered by chance, and there is insufficient evidence to address further questions regarding their adaptations and lifestyles.
'By reconstructing the geographical limitations imposed by ice sheet evolution, changes in Relative Sea Level (RSL) and river courses, it may be possible to focus on other likely locations – both onshore and offshore – and begin to uncover more evidence.'
The paper adds: 'Recovering evidence for a LUP presence in Scotland presents challenges unmatched in continental Europe. However, despite being distant from its central area, the evidence from Skye reflects an Ahrensburgian presence at the extreme north- west continental limit, extending their distribution.
'The people who made these artefacts originated in the mainland of northwest Europe, crossed Doggerland into what is now Britain, and eventually reached the far north of the Isle of Skye. Here, they adapted to live in a fragmented, fluctuating, and volatile environment amid melting glaciers, mountains, and oceans – vastly different from the low-lying environments of their homelands on the northwestern edge of the Great European Plain.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Colon cancer: Exercise as important as drugs in preventing recurrence
Colon cancer: Exercise as important as drugs in preventing recurrence

Medical News Today

time5 days ago

  • Medical News Today

Colon cancer: Exercise as important as drugs in preventing recurrence

Could exercise be 'better than a drug' at preventing colon cancer recurrence? Image credit: Connect Images/. Colorectal cancer is the third most common cancer worldwide, and the second leading cause of cancer deaths. Treatments include surgery, radiotherapy and chemotherapy. After initial treatment, people are advised to follow a healthy lifestyle, often in conjunction with further drug treatments to try and reduce the chance of recurrence. Now, a study has found that a structured exercise program could be more effective than drug treatments in preventing colon cancer recurrence. Patients following a supervised exercise program had a 28% lower risk of recurrence, and a 37% lower risk of death from any cause than those who were not. Now, a study led by Canadian scientists has found that a structured exercise program following surgery and chemotherapy for colon cancer reduced patients' chance of cancer recurring by 28% compared with patients given only health advice. Experts have said these results suggest exercise could be 'better than a drug' at preventing colon cancer recurrence. Speaking to the Science Media Centre, David Sebag-Montefiore, MB BS, MRCP, FRCP, the Audrey and Stanley Burton Professor of Clinical Oncology and Health Research, University of Leeds, United Kingdom, who was not involved in the trial, commented that: 'This is excellent news for future patients with bowel cancer and is likely to bring additional health benefits […[ The great appeal of a structured moderate intensity exercise is that is offers the benefits without the downside of the well-known side effects of our other treatments.' All those enrolled in the trial, between 2009 and 2024, had undergone surgery for stage 3 or high-risk stage 2 colon cancer, followed by adjuvant chemotherapy to help prevent the cancer returning. They ranged in age from 19 to 84 years, with a median age of 61. Most participants had a body mass index (BMI) indicating overweight or obesity, and none exercised for more than 150 minutes per week before the trial. Researchers randomly assigned all participants to one of two groups. The exercise group — made up of 445 patients — worked with a certified physical activity consultant for 3 years. For the first 6 months the consultants saw them every week, then fortnightly for the second 6 months, and monthly for next 2 years. These participants could choose the type, frequency and intensity of aerobic exercise, but the aim was to achieve the equivalent of 3-4 brisk 45-60 minute walks a week. The health-education group (444 patients) received general health-education materials promoting physical activity and healthy nutrition in addition to standard surveillance. At a median follow-up of 7.9 years, 93 people in the exercise group and 131 in the health-education group had experienced a recurrence of their cancer, a new primary cancer, or had died. In total, 107 died from any cause — 41 in the exercise group, 66 in the health-education group. People in the exercise group did not lose weight, but saw a general improvement in physical functioning and significantly longer disease-free survival, with an annual incidence of recurrence, new primary cancer, or death of 3.7%, compared with 5.4% in the health-education group. In the exercise group, 80.3% of patients were disease-free after 5 years, compared with 73.9% of the health-education group. Lead author on the study, Kerry S. Courneya, PhD, Professor and Canada Research Chair in Physical Activity and Cancer at the University of Alberta in Edmonton, Canada, told Medical News Today that the most important finding of their study was the overall improvement in survival. Julie Gralow, MD, Chief Medical Officer of the American Society of Clinical Oncology (ASCO), who was not involved in the trial, said the findings suggest that exercise could be 'better than a drug' for cancer patient outcomes, because it does not have the related side effects. However, she cautioned: 'I did not mean to suggest that we omit drugs in favor of exercise, my intention was to compare the magnitude of benefit we get from standard therapies to what exercise achieved in terms of reduction of recurrences and deaths, also taking toxicity into account.' She added that while there were effective drugs that help prevent recurrence in patients with particular mutations for colon cancer, 'exercise's benefit in colon cancer patients is not restricted to these specific mutations.' Courneya emphasized the benefits of their program: 'The 'side effects' of exercise are almost all good (fitter, stronger, less fatigue, less depression, lower [cardiovascular disease] risk, etc.). I think exercise keeps having an effect on new primary cancers and possibly other causes of death. Intervention participants were still doing more exercise than health education at years 4 and 5.' A supervised exercise program can also be much cheaper than medication. 'The [physical activity] intervention was maybe 3,000 to 5,000 [Canadian dollars] whereas it is not uncommon for some cancer drugs to be 10s of thousands and even reach 100,000,' Courneya added. Vicky Coyle, U.K. lead researcher for the trial and Clinical Professor at Queen's University Belfast, Northern Ireland, told MNT that: 'Our study gives clear, encouraging evidence that physical activity can reduce the risk of cancer returning for some people with colon cancer. We now need to work with policymakers and healthcare providers to embed exercise into treatment plans where appropriate.' Joe Henson, PhD, Associate Professor in Lifestyle Medicine at the University of Leicester, who led exercise sessions in Leicester, U.K. for the trial, highlighted the need for support. 'Despite its proven benefits, many people still face barriers to engaging in regular exercise. This study shows how important it is to make exercise advice a routine part of cancer care and to offer people tailored support,' Henson told us. Although she emphasizes the importance of exercise to her own patients, Gralow noted that implementing exercise programs like those in this study could be difficult: 'I question whether most clinics have enough personnel to accommodate this number of visits (especially since prior observational data suggests many other cancer types — including common ones like breast and prostate cancer — benefit from exercise). I also question whether all or even most patients are willing to come in this often.' 'So,' she said, 'we need to find alternative ways to support our patients in incorporating exercise into their lives that do not require clinic visits but do provide regular support and encouragement. And we need to make sure we, the clinicians, are recommending this (a prescription for exercise!).' Colorectal Cancer Cancer / Oncology Sports Medicine / Fitness

The cheap 90p supplement that could slash risk of deadly heart failure by ‘reversing' damage from silent killer
The cheap 90p supplement that could slash risk of deadly heart failure by ‘reversing' damage from silent killer

The Sun

time6 days ago

  • The Sun

The cheap 90p supplement that could slash risk of deadly heart failure by ‘reversing' damage from silent killer

A CHEAP supplement could help prevent deadly heart failure by 'reversing' damage caused by silent killer diabetes. People with type 2 diabetes who took the widely available pill daily on top of their standard treatment were able to reverse early signs of diabetes-related heart failure in a matter of months, a new study showed. 1 The number Brits with diabetes has reached an all-time high - it's estimated that 5.8 million people have the condition, 90 per cent of whom have type 2 diabetes. This number is predicted to continue surging. Type 2 diabetes patients are up to five times more likely to develop heart failure than the rest of the population, according to the British Heart Foundation (BHF). Once someone with diabetes is diagnosed with heart failure, they are three times more likely to die over the next five years. But a study conducted by the University of Leeds found that diabetics who took mitoquinone - sold as a health supplement for about 90p per tablet - had healthier hearts after four months compared to those not given the supplement. Lead author Dr Henry Procter, a clinical research fellow at the University of Leeds, said: 'These encouraging results are a sign that mitoquinone could keep hearts healthier for longer in people with diabetes. "If the study had continued for longer, it is likely we would have started to see differences in more serious indicators of heart health between the group with mitoquinone and the group without.' Diabetes causes problems with how the body - including the heart - processes and uses energy, which can cause stress and damage to the cells of the heart muscle. Over time, it can lead to the heart stiffening and being unable to pump blood well, eventually to the point of heart failure. Mitoquinone is an artificial antioxidant that is thought to guard cells against this metabolic stress and damage. It's sold online as a supplement for about £50 for a jar of 60 pills, which works out at about 86p per tablet. However, these are at doses far lower than those used in the study. The research, whose results were presented at the British Cardiovascular Society conference in Manchester, involved 70 patients with type 2 diabetes who didn't have heart failure. Half were given 40mg of mitoquinone per day on top of their regular diabetes treatment, while the other half received their usual medication. Both groups had their heart health assessed at the start of the study and again four months later. After four months of mitoquinone, diabetic patients' hearts were able to process and use energy 15 per cent more efficiently. Their heart muscles were also able to relax more quickly, which showed that early indicators of stress and stiffness in their hearts had been reversed, according to researchers. Patients experienced no side effects from taking the supplement. What is heart failure and tips to prevent it Heart failure is a condition where your heart can't pump blood around your body as well as it should. It doesn't mean your heart has stopped working but you may need support to help it work better. When your heart isn't pumping blood as well as it should, it means you're not getting enough oxygen. This affects how your body works, including your breathing and muscles. This causes some of the main symptoms of heart failure, like: Fainting or feeling lightheaded Feeling increasingly tired or weak at rest which gets worse with movement New persistent cough Shortness of breath when you're active or resting Swelling in your feet and ankles which can spread to your lower body You should see your GP as soon as you can if you experience any of these symptoms. To manage heart failure, here are some things you could try: Keeping active – which has been proven to boost energy and improve sleep and quality of life. Keeping to a healthy weight and diet – this will help your overall health and prevent extra strain on your heart. Limiting how much alcohol you drink (less than the recommended 14 units per week) - lowering your chance of getting abnormal heart rhythms, high blood pressure and diseases such as stroke, liver problems and some cancers. Stopping smoking and using other tobacco products - reducing your risk of developing heart and circulatory diseases. Watching the amount of fluid you have each day if advised by your medical team. Weighing yourself regularly – sudden weight gain may mean too much fluid is building up in your body and will need treated. Source: BHF Those who didn't take the daily pill didn't see the same improvements to their heart health. Experts said that while their findings are promising they now need to be backed up by larger trials. The research team is now looking into running a larger study of mitoquinone in diabetes patients, to gather more evidence that the supplement could protect their hearts and prevent heart failure over time. They hope to show that diabetes patients could one day be prescribed mitoquinone to keep their hearts healthier for longer. 'We hope that a larger study will continue to demonstrate the benefits of this antioxidant, and that one day soon diabetic patients can be prescribed it to help prevent heart failure before it ever affects their lives," Dr Procter said. Professor Bryan Willians, the BHF's chief scientific and medical officer, added: 'This study presents some intriguing initial findings. "It's still early days for this research and the results will need to be confirmed in a larger scale trial. "The study neatly demonstrates why it is so important to continue to support research and look for solutions in a wide variety of places, so that we can continue to offer hope to people living with, and at risk of, cardiovascular disease.'

Major study finds 90p supplement could slash risk of sudden heart death: 'Reverses' signs of deadly disease
Major study finds 90p supplement could slash risk of sudden heart death: 'Reverses' signs of deadly disease

Daily Mail​

time7 days ago

  • Daily Mail​

Major study finds 90p supplement could slash risk of sudden heart death: 'Reverses' signs of deadly disease

A cheap supplement could help prevent potentially deadly heart failure among patients with type 2 diabetes, research suggests. More than 5million people in the UK are thought to suffer from type 2 diabetes, which is often referred to as a 'silent killer', with rates having soared in recent years. But now scientists have found patients taking a substance called mitoquinone—sold as a health supplement for about 90p per tablet—had healthier hearts than those in a control group. Scientists behind the study said the results could save lives given how patients with type 2 diabetes have five times the risk of suffering heart failure compared to someone without the condition. In the trial, patients on mitoquinone even had signs that the damage their hearts had suffered from diabetes had been 'reversed'. However, experts have said while their findings are promising they now need to be backed up by larger trials. Mitoquinone is an artificial antioxidant—a substance that helps protect cells—which is a modified version of an antioxidant naturally found in the body called CoQ10. Dr Henry Procter, an expert in heart health at University of Leeds and lead author of the four month study, said the results were 'encouraging'. 'If the study had continued for longer, it is likely we would have started to see differences in more serious indicators of heart health between the group with mitoquinone and the group without,' he said. 'We hope that a larger study will continue to demonstrate the benefits of this antioxidant, and that one day soon diabetic patients can be prescribed it to help prevent heart failure before it ever affects their lives.' In the trial, the results of which were presented at the British Cardiovascular Society conference in Manchester, involved 70 patients with type 2 diabetes without heart failure. Half were given 40mg of mitoquinone per day in addition to their regular diabetes treatment, while the other half just received their usual medication. Both groups had their heart health assessed at the start of the study and again four months later. At the end of the trial the group on mitoquinone were found to have hearts that performed 15 per cent more efficiently than at the start of the study. The mitoquinone group were also found to have improvements in exercise tests, with their hearts also able to relax more quickly after exertion. Researchers said these were signs that the stress and stiffness the organ suffers from diabetes had been reversed. Diabetes damages the heart by interfering with how the organ processes and uses energy. Over time this interference causes stress and harms the cells of the heart muscle, leading to it becoming stiff and having to work harder to pump blood around the body, increasing the risk of heart failure. Mitoquinone is thought to help protect the cells from this damage. The substance is sold online as a health supplement for about £50 for a jar of 60 pills, which works out at about 86p per tablet. However, these are at doses far lower than those used in the study. Critically, no adverse side effects were reported in the group taking mitoquinone. The scientists are now hoping to run another similar trial with a larger group of patients to add more weight to their findings. If the results are supported by future studies the experts hope diabetes patients could one day be prescribed mitoquinone to help protect their hearts for longer. Heart failure is an incurable condition where the organ can't pump blood around the body as well as it should. The condition tends to get worse over time and is often eventually fatal. Once a diabetes patient is diagnosed with heart failure it triples their risk of dying within the next five years. Reacting to the study, Professor Bryan Willians, chief scientific and medical officer at the charity the British Heart Foundation, said it was a promising start. 'It's still early days for this research and the results will need to be confirmed in a larger scale trial,' he said. 'The study neatly demonstrates why it is so important to continue to support research and look for solutions in a wide variety of places, so that we can continue to offer hope to people living with, and at risk of, cardiovascular disease.' Almost 6million Britons have diabetes, of which 90 per cent is type 2, but charities estimate 1.2million are living with the disease undiagnosed. While nationally, an estimated 8 per cent of the population of England has the disease, this rises to over one in 10 people in some parts of the country. Type 2 diabetes occurs when the body doesn't make enough insulin or the insulin it makes doesn't work properly. Insulin is a hormone critical to controlling blood sugar levels. Having high blood sugar levels over time can cause heart attacks and strokes, as well as problems with the eyes, kidneys and feet. Sufferers may need to overhaul their diet, take daily medication and have regular check-ups. Symptoms of the condition, which is diagnosed with a blood test, include excessive thirst, tiredness and needing to urinate more often. But many people have no signs.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store